Kayne Anderson Rudnick Investment Management
FOLD

Kayne Anderson Rudnick Investment Management’s Amicus Therapeutics FOLD Stock Holding History

Kayne Anderson Rudnick Investment Management’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-223
Closed -$2K – 630
2022
Q1 		$2K Buy
+223
New +$2.09K ﹤0.01% 592

Other funds holding FOLD

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Kayne Anderson Rudnick Investment Management's FOLD Position: Q2 2022 in Review

Kayne Anderson Rudnick Investment Management sold out of Amicus Therapeutics (FOLD) in Q2 2022, closing a stake of 223 shares — an estimated $2K sold.

Kayne Anderson Rudnick Investment Management first reported a position in FOLD in Q1 2022 and held it in 1 quarter. The position peaked at $2K in Q1 2022. 212 funds tracked by Wall St. Rank hold FOLD as of Q2 2022.

  • Kayne Anderson Rudnick Investment Management reported no remaining Amicus Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Kayne Anderson Rudnick Investment Management sold 223 Amicus Therapeutics shares in Q2 2022, an estimated $2K.
  • Kayne Anderson Rudnick Investment Management first reported a position in Amicus Therapeutics in Q1 2022 and held it in 1 quarter.
  • Kayne Anderson Rudnick Investment Management's Amicus Therapeutics position peaked at $2K in Q1 2022.
  • 212 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q2 2022.

Based on Kayne Anderson Rudnick Investment Management's 13F filing for Q2 2022, filed 12 Aug 2022.